持续气道正压通气对阻塞性睡眠呼吸暂停综合征患者血清可溶性凝集素样氧化低密度脂蛋白受体1水平的影响

Effect of continuous positive airway pressure on serum soluble lectin-like oxidized low-density lipoprotein receptor-1 level in patients with obstructive sleep apnea syndrome

目的评价阻塞性睡眠呼吸暂停综合征（OSAS）血清凝集素样氧化低密度脂蛋白受体-1（sLOX-1）水平及持续气道正压通气治疗（CPAP）对OSAS患者血清sLOX-1水平的影响。方法选取经多导睡眠呼吸监测诊断的中重度OSAS患者20例（OSAS组）及对照者15例（正常组），测定血清sLOX-1水平；OSAS组经CPAP治疗1周前后血清sLOX-1水平变化。结果OSAS组治疗前血清sLOX-1含量为（105．26±37．47）pg／,nl，显著高于健康对照组的（99．98±18．78）pg／ml，差异有统计学意义（P〈0．05）。经过CPAP治疗1周后，OSAS组血清sLOX-1水平降至（93．34±21．24）pg／ml，明显低于治疗前，差异有统计学意义（P〈0．05）。OSAS组治疗前血清sLOX-1水平与AHI呈正相关（r=0．416，1P〈0．05）。结论OSAS患者血清sLOX-1水平升高，持续气道正压通气治疗可有效降低OSAS患者血清sLOX-1水平。

Objective To evaluate serum soluble lectin-like oxidized low density lipoprotein receptor -1 （sLOX-1） level in patients with obstructive sleep apnea syndrome （OSAS） and effect of continuous positive airway pressure （CPAP） on serum sLOX-1 level in patients with OSAS. Methods Twenty cases of moderate and severe OSAS patients were selected as the OSAS group by means ofpolysomnography （PSG）, and 15 healthy cases were enrolled as the control group. The serum sLOX-1 levels were measured in the OSAS group and the control group. After treatment with CPAP in the OSAS group, the serum sLOX-1 level was measured again. Results Before treatment, the serum sLOX-1 level was （105.26±37.47） pg/ml in the OSAS group, in which the serum sLOX-1 level was significantly higher than that in the control group [（99.98±18.78） pg/ml] （P 〈 0.05）. After 1 week CPAP treatment in the OSAS group, the serum sLOX-1 level dropped to （93.34±21.24） pg/ml. Comparing the levels between before and after treatment, the difference was statistically significant （P 〈 0.05）. Before treatment in the OSAS group, the serum sLOX-1 level was positively correlated with apnea hyponea index （AHI） （r = 0.416, P 〈 0.05）. Conclusion The level of serum sLOX-1 increases in patients with OSAS. CPAP can effectively reduce the level of serum sLOX-1 in patients with OSAS.